{"id":538173,"date":"2021-09-14T16:08:21","date_gmt":"2021-09-14T20:08:21","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/veracyte-announces-that-new-nccn-guidelines-uniquely-recommend-use-of-decipher-prostate-genomic-test-score-to-guide-specific-treatment-for-men-following-radical-prostatectomy\/"},"modified":"2021-09-14T16:08:21","modified_gmt":"2021-09-14T20:08:21","slug":"veracyte-announces-that-new-nccn-guidelines-uniquely-recommend-use-of-decipher-prostate-genomic-test-score-to-guide-specific-treatment-for-men-following-radical-prostatectomy","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/veracyte-announces-that-new-nccn-guidelines-uniquely-recommend-use-of-decipher-prostate-genomic-test-score-to-guide-specific-treatment-for-men-following-radical-prostatectomy\/","title":{"rendered":"Veracyte Announces that New NCCN Guidelines Uniquely Recommend Use of Decipher Prostate Genomic Test Score to Guide Specific Treatment for Men Following Radical Prostatectomy"},"content":{"rendered":"

<\/p>\n

Veracyte Announces that New NCCN Guidelines Uniquely Recommend Use of Decipher Prostate Genomic Test Score to Guide Specific Treatment for Men Following Radical Prostatectomy<\/b><\/p>\n

SOUTH SAN FRANCISCO, Calif.–(BUSINESS WIRE<\/a>)–Veracyte, Inc<\/a>. (Nasdaq: VCYT) today announced that its Decipher\u00ae<\/sup> Prostate RP genomic classifier is uniquely recommended in the 2022 National Comprehensive Cancer Network\u00ae<\/sup> (NCCN) Clinical Practice Guidelines for Oncology to guide treatment decisions for men with prostate cancer. The new guidelines specifically recommend Decipher Prostate RP after radical prostatectomy and that men with high-risk scores (>0.6) should be strongly considered for salvage radiotherapy with the addition of concurrent hormone therapy, when early radiation therapy is missed.\n<\/p>\n

\n\u201cWe are thrilled that Decipher Prostate RP is now recommended by the NCCN to guide specific treatment decisions,\u201d said Elai Davicioni, Ph.D., Veracyte\u2019s senior vice president, scientific and clinical operations, urologic cancers. \u201cThe NCCN\u2019s designation is unique to Decipher Prostate RP and underscores the extensive clinical validation and clinical utility data behind the test. We believe this recommendation will ultimately enable more men to receive the treatment they need, while reducing unnecessary therapy.\u201d\n<\/p>\n

\nThe new NCCN recommendations are based on results of the NRG Oncology Phase 3 randomized controlled trial, RTOG 96-01. This study<\/a>, which followed patients for a median of 12 years, demonstrated that Decipher risk results were associated with hormone therapy benefit, with Decipher high-risk men receiving greater absolute benefit from hormone therapy compared to Decipher low-risk men. In the subset of patients who received hormone therapy in addition to early salvage radiotherapy, Decipher high-risk men experienced improvements in distant metastasis, prostate cancer-specific mortality and overall survival, while Decipher low-risk men had good oncologic outcomes without hormone therapy.\n<\/p>\n

\nThe Decipher Prostate genomic classifier is currently being investigated in seven National Cancer Institute-sponsored, Phase 3, prospective, randomized controlled clinical trials; 13 Phase 2\/3 prospective trials; and more than 20 retrospective studies of Phase 3 randomized controlled trials. Many of these trials require Decipher Prostate testing for study inclusion.\n<\/p>\n

About Decipher Prostate <\/b><\/p>\n

\nDecipher Prostate (Decipher Prostate Biopsy and Decipher Prostate RP) is a 22-gene, whole-transcriptome-developed genomic test intended to help inform treatment decisions for men with localized prostate cancer at initial diagnosis and after surgical removal of the prostate. The test reports the Decipher Score, which prognosticates a patient’s risk of metastasis within five years and provides risk estimates of prostate cancer-specific outcomes. Decipher Prostate can help guide physicians to better select the appropriate therapy for a specific patient, which in turn can result in improved patient outcomes.\n<\/p>\n

About Veracyte<\/b><\/p>\n

\nVeracyte (Nasdaq: VCYT) is a global diagnostics company that improves patient care by providing answers to clinical questions, informing diagnosis and treatment decisions throughout the patient journey in cancer and other diseases. The company\u2019s growing menu of genomic tests leverages advances in genomic science and technology, enabling patients to avoid risky, costly diagnostic procedures and quicken time to appropriate treatment. The company\u2019s tests in lung cancer, prostate cancer, breast cancer, thyroid cancer, bladder cancer, colon cancer and idiopathic pulmonary fibrosis are available to patients and its renal cancer and lymphoma subtyping tests are in development, the latter as a companion diagnostic. With Veracyte\u2019s exclusive global license to a best-in-class diagnostics instrument platform, the company is positioned to deliver its tests to patients worldwide. Veracyte is based in South San Francisco, California. For more information, please visit www.veracyte.com<\/a> and follow the company on Twitter (@veracyte).\n<\/p>\n

Cautionary Note Regarding Forward-Looking Statements <\/b><\/p>\n

\nThis press release contains forward-looking statements, including, but not limited to, our statements related to our plans, objectives, expectations (financial and otherwise) regarding the Decipher Prostate RP Genomic Classifier\u2019s ability to provide prognostic information that can help guide treatment decisions for prostate cancer patients who are candidates for salvage radiotherapy. Forward-looking statements can be identified by words such as: “anticipate,” “intend,” “plan,” “expect,” “believe,” “should,” \u201csuggest,\u201d “may,” “will” and similar references to future periods. Actual results may differ materially from those projected or suggested in any forward-looking statements. These statements involve risks and uncertainties, which could cause actual results to differ materially from our predictions, and include, but are not limited to, the benefits of Veracyte\u2019s tests and the applicability of clinical results to actual outcomes. Additional factors that may impact these forward-looking statements can be found under the caption \u201cRisk Factors\u201d in our Annual Report on Form 10-K filed with the SEC on February 22, 2021, and our subsequent quarterly reports on Form 10-Q. A copy of these documents can be found at the Investors section of our website at . These forward-looking statements speak only as of the date hereof and, except as required by law, Veracyte specifically disclaims any obligation to update these forward-looking statements or reasons why actual results might differ, whether as a result of new information, future events or otherwise.www.veracyte.com<\/a><\/span>. These forward-looking statements speak only as of the date hereof and, except as required by law, Veracyte specifically disclaims any obligation to update these forward-looking statements or reasons why actual results might differ, whether as a result of new information, future events or otherwise.\n<\/p>\n

\nVeracyte, the Veracyte logo, HalioDx, Decipher, Decipher GRID, Afirma, Percepta, Envisia, Prosigna, Lymphmark, \u201cKnow by Design\u201d and \u201cMore about You\u201d are registered trademarks of Veracyte, Inc. and its affiliates in the U.S. and selected countries. nCounter is the registered trademark of NanoString Technologies, Inc. in the U.S. and selected countries and used by Veracyte under license.\n<\/p>\n

\"\"<\/p>\n

View source version on businesswire.com: <\/span>https:\/\/www.businesswire.com\/news\/home\/20210914006008\/en\/<\/a><\/span><\/p>\n

Investor and Media Contact:
\n<\/b>
Tracy Morris
\n
Vice President of Corporate Communications & Investor Relations
\n
tracy.morris@veracyte.com
\n<\/a>
650-380-4413\n<\/p>\n

KEYWORDS:<\/b> United States North America California<\/p>\n

INDUSTRY KEYWORDS:<\/b> Research Medical Devices Clinical Trials Biotechnology General Health Pharmaceutical Health Science Oncology Other Science<\/p>\n

MEDIA:<\/b><\/p>\n\n\n\n\n
Logo<\/b><\/font><\/td>\n<\/tr>\n
\"Logo\"<\/td>\n<\/tr>\n
<\/font><\/td>\n<\/tr>\n<\/table>\n","protected":false},"excerpt":{"rendered":"

Veracyte Announces that New NCCN Guidelines Uniquely Recommend Use of Decipher Prostate Genomic Test Score to Guide Specific Treatment for Men Following Radical Prostatectomy SOUTH SAN FRANCISCO, Calif.–(BUSINESS WIRE)–Veracyte, Inc. (Nasdaq: VCYT) today announced that its Decipher\u00ae Prostate RP genomic classifier is uniquely recommended in the 2022 National Comprehensive Cancer Network\u00ae (NCCN) Clinical Practice Guidelines for Oncology to guide treatment decisions for men with prostate cancer. The new guidelines specifically recommend Decipher Prostate RP after radical prostatectomy and that men with high-risk scores (>0.6) should be strongly considered for salvage radiotherapy with the addition of concurrent hormone therapy, when early radiation therapy is missed. \u201cWe are thrilled that Decipher Prostate RP is now recommended by the NCCN to guide specific … <\/p>\n

Continue reading “Veracyte Announces that New NCCN Guidelines Uniquely Recommend Use of Decipher Prostate Genomic Test Score to Guide Specific Treatment for Men Following Radical Prostatectomy”<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-538173","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"\nVeracyte Announces that New NCCN Guidelines Uniquely Recommend Use of Decipher Prostate Genomic Test Score to Guide Specific Treatment for Men Following Radical Prostatectomy - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/veracyte-announces-that-new-nccn-guidelines-uniquely-recommend-use-of-decipher-prostate-genomic-test-score-to-guide-specific-treatment-for-men-following-radical-prostatectomy\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Veracyte Announces that New NCCN Guidelines Uniquely Recommend Use of Decipher Prostate Genomic Test Score to Guide Specific Treatment for Men Following Radical Prostatectomy - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"Veracyte Announces that New NCCN Guidelines Uniquely Recommend Use of Decipher Prostate Genomic Test Score to Guide Specific Treatment for Men Following Radical Prostatectomy SOUTH SAN FRANCISCO, Calif.–(BUSINESS WIRE)–Veracyte, Inc. (Nasdaq: VCYT) today announced that its Decipher\u00ae Prostate RP genomic classifier is uniquely recommended in the 2022 National Comprehensive Cancer Network\u00ae (NCCN) Clinical Practice Guidelines for Oncology to guide treatment decisions for men with prostate cancer. The new guidelines specifically recommend Decipher Prostate RP after radical prostatectomy and that men with high-risk scores (>0.6) should be strongly considered for salvage radiotherapy with the addition of concurrent hormone therapy, when early radiation therapy is missed. \u201cWe are thrilled that Decipher Prostate RP is now recommended by the NCCN to guide specific … Continue reading "Veracyte Announces that New NCCN Guidelines Uniquely Recommend Use of Decipher Prostate Genomic Test Score to Guide Specific Treatment for Men Following Radical Prostatectomy"\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/veracyte-announces-that-new-nccn-guidelines-uniquely-recommend-use-of-decipher-prostate-genomic-test-score-to-guide-specific-treatment-for-men-following-radical-prostatectomy\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2021-09-14T20:08:21+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20210914006008r1&sid=flmnd&distro=nx&lang=en\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"5 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/veracyte-announces-that-new-nccn-guidelines-uniquely-recommend-use-of-decipher-prostate-genomic-test-score-to-guide-specific-treatment-for-men-following-radical-prostatectomy\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/veracyte-announces-that-new-nccn-guidelines-uniquely-recommend-use-of-decipher-prostate-genomic-test-score-to-guide-specific-treatment-for-men-following-radical-prostatectomy\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Veracyte Announces that New NCCN Guidelines Uniquely Recommend Use of Decipher Prostate Genomic Test Score to Guide Specific Treatment for Men Following Radical Prostatectomy\",\"datePublished\":\"2021-09-14T20:08:21+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/veracyte-announces-that-new-nccn-guidelines-uniquely-recommend-use-of-decipher-prostate-genomic-test-score-to-guide-specific-treatment-for-men-following-radical-prostatectomy\\\/\"},\"wordCount\":977,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/veracyte-announces-that-new-nccn-guidelines-uniquely-recommend-use-of-decipher-prostate-genomic-test-score-to-guide-specific-treatment-for-men-following-radical-prostatectomy\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20210914006008r1&sid=flmnd&distro=nx&lang=en\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/veracyte-announces-that-new-nccn-guidelines-uniquely-recommend-use-of-decipher-prostate-genomic-test-score-to-guide-specific-treatment-for-men-following-radical-prostatectomy\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/veracyte-announces-that-new-nccn-guidelines-uniquely-recommend-use-of-decipher-prostate-genomic-test-score-to-guide-specific-treatment-for-men-following-radical-prostatectomy\\\/\",\"name\":\"Veracyte Announces that New NCCN Guidelines Uniquely Recommend Use of Decipher Prostate Genomic Test Score to Guide Specific Treatment for Men Following Radical Prostatectomy - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/veracyte-announces-that-new-nccn-guidelines-uniquely-recommend-use-of-decipher-prostate-genomic-test-score-to-guide-specific-treatment-for-men-following-radical-prostatectomy\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/veracyte-announces-that-new-nccn-guidelines-uniquely-recommend-use-of-decipher-prostate-genomic-test-score-to-guide-specific-treatment-for-men-following-radical-prostatectomy\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20210914006008r1&sid=flmnd&distro=nx&lang=en\",\"datePublished\":\"2021-09-14T20:08:21+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/veracyte-announces-that-new-nccn-guidelines-uniquely-recommend-use-of-decipher-prostate-genomic-test-score-to-guide-specific-treatment-for-men-following-radical-prostatectomy\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/veracyte-announces-that-new-nccn-guidelines-uniquely-recommend-use-of-decipher-prostate-genomic-test-score-to-guide-specific-treatment-for-men-following-radical-prostatectomy\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/veracyte-announces-that-new-nccn-guidelines-uniquely-recommend-use-of-decipher-prostate-genomic-test-score-to-guide-specific-treatment-for-men-following-radical-prostatectomy\\\/#primaryimage\",\"url\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20210914006008r1&sid=flmnd&distro=nx&lang=en\",\"contentUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20210914006008r1&sid=flmnd&distro=nx&lang=en\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/veracyte-announces-that-new-nccn-guidelines-uniquely-recommend-use-of-decipher-prostate-genomic-test-score-to-guide-specific-treatment-for-men-following-radical-prostatectomy\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Veracyte Announces that New NCCN Guidelines Uniquely Recommend Use of Decipher Prostate Genomic Test Score to Guide Specific Treatment for Men Following Radical Prostatectomy\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Veracyte Announces that New NCCN Guidelines Uniquely Recommend Use of Decipher Prostate Genomic Test Score to Guide Specific Treatment for Men Following Radical Prostatectomy - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/veracyte-announces-that-new-nccn-guidelines-uniquely-recommend-use-of-decipher-prostate-genomic-test-score-to-guide-specific-treatment-for-men-following-radical-prostatectomy\/","og_locale":"en_US","og_type":"article","og_title":"Veracyte Announces that New NCCN Guidelines Uniquely Recommend Use of Decipher Prostate Genomic Test Score to Guide Specific Treatment for Men Following Radical Prostatectomy - Market Newsdesk","og_description":"Veracyte Announces that New NCCN Guidelines Uniquely Recommend Use of Decipher Prostate Genomic Test Score to Guide Specific Treatment for Men Following Radical Prostatectomy SOUTH SAN FRANCISCO, Calif.–(BUSINESS WIRE)–Veracyte, Inc. (Nasdaq: VCYT) today announced that its Decipher\u00ae Prostate RP genomic classifier is uniquely recommended in the 2022 National Comprehensive Cancer Network\u00ae (NCCN) Clinical Practice Guidelines for Oncology to guide treatment decisions for men with prostate cancer. The new guidelines specifically recommend Decipher Prostate RP after radical prostatectomy and that men with high-risk scores (>0.6) should be strongly considered for salvage radiotherapy with the addition of concurrent hormone therapy, when early radiation therapy is missed. \u201cWe are thrilled that Decipher Prostate RP is now recommended by the NCCN to guide specific … Continue reading \"Veracyte Announces that New NCCN Guidelines Uniquely Recommend Use of Decipher Prostate Genomic Test Score to Guide Specific Treatment for Men Following Radical Prostatectomy\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/veracyte-announces-that-new-nccn-guidelines-uniquely-recommend-use-of-decipher-prostate-genomic-test-score-to-guide-specific-treatment-for-men-following-radical-prostatectomy\/","og_site_name":"Market Newsdesk","article_published_time":"2021-09-14T20:08:21+00:00","og_image":[{"url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20210914006008r1&sid=flmnd&distro=nx&lang=en","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"5 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/veracyte-announces-that-new-nccn-guidelines-uniquely-recommend-use-of-decipher-prostate-genomic-test-score-to-guide-specific-treatment-for-men-following-radical-prostatectomy\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/veracyte-announces-that-new-nccn-guidelines-uniquely-recommend-use-of-decipher-prostate-genomic-test-score-to-guide-specific-treatment-for-men-following-radical-prostatectomy\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Veracyte Announces that New NCCN Guidelines Uniquely Recommend Use of Decipher Prostate Genomic Test Score to Guide Specific Treatment for Men Following Radical Prostatectomy","datePublished":"2021-09-14T20:08:21+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/veracyte-announces-that-new-nccn-guidelines-uniquely-recommend-use-of-decipher-prostate-genomic-test-score-to-guide-specific-treatment-for-men-following-radical-prostatectomy\/"},"wordCount":977,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/veracyte-announces-that-new-nccn-guidelines-uniquely-recommend-use-of-decipher-prostate-genomic-test-score-to-guide-specific-treatment-for-men-following-radical-prostatectomy\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20210914006008r1&sid=flmnd&distro=nx&lang=en","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/veracyte-announces-that-new-nccn-guidelines-uniquely-recommend-use-of-decipher-prostate-genomic-test-score-to-guide-specific-treatment-for-men-following-radical-prostatectomy\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/veracyte-announces-that-new-nccn-guidelines-uniquely-recommend-use-of-decipher-prostate-genomic-test-score-to-guide-specific-treatment-for-men-following-radical-prostatectomy\/","name":"Veracyte Announces that New NCCN Guidelines Uniquely Recommend Use of Decipher Prostate Genomic Test Score to Guide Specific Treatment for Men Following Radical Prostatectomy - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/veracyte-announces-that-new-nccn-guidelines-uniquely-recommend-use-of-decipher-prostate-genomic-test-score-to-guide-specific-treatment-for-men-following-radical-prostatectomy\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/veracyte-announces-that-new-nccn-guidelines-uniquely-recommend-use-of-decipher-prostate-genomic-test-score-to-guide-specific-treatment-for-men-following-radical-prostatectomy\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20210914006008r1&sid=flmnd&distro=nx&lang=en","datePublished":"2021-09-14T20:08:21+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/veracyte-announces-that-new-nccn-guidelines-uniquely-recommend-use-of-decipher-prostate-genomic-test-score-to-guide-specific-treatment-for-men-following-radical-prostatectomy\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/veracyte-announces-that-new-nccn-guidelines-uniquely-recommend-use-of-decipher-prostate-genomic-test-score-to-guide-specific-treatment-for-men-following-radical-prostatectomy\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/veracyte-announces-that-new-nccn-guidelines-uniquely-recommend-use-of-decipher-prostate-genomic-test-score-to-guide-specific-treatment-for-men-following-radical-prostatectomy\/#primaryimage","url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20210914006008r1&sid=flmnd&distro=nx&lang=en","contentUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20210914006008r1&sid=flmnd&distro=nx&lang=en"},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/veracyte-announces-that-new-nccn-guidelines-uniquely-recommend-use-of-decipher-prostate-genomic-test-score-to-guide-specific-treatment-for-men-following-radical-prostatectomy\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Veracyte Announces that New NCCN Guidelines Uniquely Recommend Use of Decipher Prostate Genomic Test Score to Guide Specific Treatment for Men Following Radical Prostatectomy"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/538173","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=538173"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/538173\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=538173"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=538173"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=538173"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}